Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Aug 24;104(19):8267–8278. doi: 10.1007/s00253-020-10842-2

Characterization of anti-BCG benz[α]anthraquinones and new siderophores from a Xinjiang desert–isolated rare actinomycete Nocardia sp. XJ31

Li Zhang 1,2,3,#, Jingyu Zhang 1,#, Biao Ren 4, Wanying Lu 1, Chengjian Hou 1, Jian Wang 2, Xiaolong Ma 2, Rong Ma 1, Mei Liu 2, Zhiheng Liu 2, Jin-Ping Li 5, Kan Ding 6,7, Huanqin Dai 2,✉, Lixin Zhang 1, Xueting Liu 1,✉
PMCID: PMC7443361  PMID: 32830291

Abstract

Abstract

The current global demand for novel anti-TB drugs has drawn urgent attention on the discovery of natural product compounds with anti-TB activity. Lots of efforts have emphasized on environmental samples from unexplored or underexplored natural habits and identified numerous rare actinomycete taxa producing structurally diverse bioactive natural products. Herein, we report a survey of the rare actinobacteria diversity in Xinjiang region together with the discovery of anti-TB active natural products from these strains. We have collected 17 soil samples at different sites with different environmental conditions, from which 39 rare actinobacteria were identified by using a selective isolation strategy with 5 media variations. Among those isolated strains, XJ31 was identified as a new Nocardia sp. based on 16S rRNA gene analysis. Through one strain-many compounds (OSMAC) strategy combined with anti-Bacillus Calmette-Guérin bioassay-guided isolation, two groups of compounds were identified. They were twelve siderophores (nocardimicins, 1-12) and two anthraquinones (brasiliquinones, 13 and 14) and ten of them were identified as new compounds. The structures of the purified compounds were elucidated using HR-ESI-MS, 1D NMR, and 2D NMR techniques. The anti-TB bioassays revealed that the two benz[α]anthraquinones have potent activity against BCG (MICs = 25 μM), which can be used as a promising start point for further anti-TB drug development.

Key points

• Ten new natural products were identified from Nocardia sp. XJ31.

• Brasiliquinones 13 and 14 showed moderate anti-BCG activity.

Electronic supplementary material

The online version of this article (10.1007/s00253-020-10842-2) contains supplementary material, which is available to authorized users.

Keywords: Xinjiang desert, Nocardia sp., Anti-BCG, Brasiliquinone, Nocardimicin

Introduction

Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis and is one of the top 10 global causes of death caused by a single infectious agent. According to a WHO report, TB caused 1.3 million deaths in 2018, and 10.0 million people are estimated to have developed TB in 2017. More than 90% of the infection cases occur in developing countries such as India (27%), China (9%), and Indonesia (8%) (WHO 2018). In addition, the high incidence of HIV/TB co-infection, together with the emergence of multi-drug-resistant M. tuberculosis strains, is now believed to pose a huge threat to global human health (Mesfin et al. 2014). Currently, anti-TB treatment is largely limited to drugs which were developed decades ago like ethionamide (1960), ethambutol (1961), capreomycin (1963), and rifampicin (1963) (Liu et al. 2016). Despite the recent approval of two new drugs, bedaquiline (2012) (Andries et al. 2005) and delamanid (2014) (Matsumoto et al. 2006), there is still a rising need for novel anti-TB drugs due to the fact that acquired resistance has been observed in therapy process (Bloemberg et al. 2015). Anti-TB drug discovery has not kept pace with increasing levels of drug resistance (Dheda et al. 2017) and efforts are being made to discover such compounds.

Natural products (NPs) are small molecules evolutionary selected by nature (in some sense pre-validated for bioactivity) that often display unique chemical diversity (Cragg and Newman 2013; Liu et al. 2012; Newman and Cragg 2016). Seven out of 11 currently used nature-derived TB drugs were either isolated from microbes or semi-synthesized from microbial natural products (Liu et al. 2016), and almost 60% of the antibiotics that are currently used in clinic for TB treatment are produced by Streptomyces (Ashforth et al. 2010). Driven by substantial overlap in the structures of newly discovered anti-TB compounds from Streptomyces, researchers have begun to focus on rare actinobacteria, which are viewed as vast potential reservoirs of novel NPs (Dhakal et al. 2017). Microbes from extreme environments such as deep-sea sediments and hot springs harbor unique secondary metabolite biosynthesis genes and possess high potentials of chemical space (Jiang et al. 2014; Okoro et al. 2009; Pettit 2011). Microorganisms from extreme environments have received extensive research attention because they can yield basic biological insights via comparisons of more widespread physiological processes versus the unique physiological mechanisms that allow them to exist and even thrive in extreme conditions (Meklat et al. 2011). These microorganisms are known to produce many structurally diverse NPs (Katz and Baltz 2016).

In the course of our previous screening work seeking for anti-TB NPs from microorganisms, we have developed a screening assay that tests the compound’s growth inhibitory activity against Bacillus Calmette-Guérin (BCG), which is an attenuated strain of the bovine tuberculosis bacillus M. bovis (Ashforth et al. 2010; Huang et al. 2016; Liu et al. 2014a; Wang et al. 2013). Here, we examined the biodiversity of rare actinobacteria sampled from extreme environments in the Xinjiang region and investigated their anti-BCG natural products. Seventeen samples were collected from different sites from diverse ecological systems in Xinjiang, resulting in isolation of 260 actinomycete strains. Phylogeny analysis of 40 strains with distinct morphological features indicated the presence of strains from 8 genera, highlighting the biodiversity of the rare actinobacteria present in these locations. Strain XJ31 of the Nocardia genus was examined in detail and a systematic natural product profiling and isolation program led to the purification and structural elucidation of 14 compounds from XJ31 based on HR-ESI-MS, 1D NMR, and 2D NMR techniques. Twelve of these compounds are oligopeptides (siderophores), including nocardimicin B (1), nocardimicin D (2), nocardimicin F (3), and nocardimicins J-R (4-12), while the remaining two are the benz[α]anthraquinones brasiliquinones D (13) and E (14). Notably, 10 out of the 14 compounds described in this study have not been reported previously (4-12 and 14), and the two benz[α]anthraquinones showed good activity against BCG (MICs = 25 μM) in bioassays.

Materials and methods

General experimental procedures

NMR spectra were obtained on a Bruker Avance DRX500 spectrometer (Bruker, Billerica, USA). Chemical shifts were calibrated internally against residual solvent signals (Pyridine-d5: δC 123.87/135.91/150.35, δH 7.22/7.58/8.74; CD3OD: δC 49.0, δH 3.31/4.87). HR-ESI-MS analysis was conducted on a Bruker micrOTOF mass spectrometer. Resin HP-20 (Diaion, Osaki, Japan), Sephadex LH-20 (GE Healthcare BioSciences AB, Marlborough, USA), and ODS-A (YMC, Wesel, Germany) were used for isolation. HPLC analysis was performed using an Agilent 1100 Series HPLC; data analysis was conducted using ChemStation Rev.B.02.01 software.

Isolation of rare actinobacteria by selective isolation methods

The actinomycete-selective isolation media (Table S1) used in the present study comprised HV agar (Hayakawa and Nonomura 1987), SM3 agar (Tan et al. 2006), MOPS agar, Starch-Casein-Nitrate agar (Küster and Williams 1964), and AV (arginine vitamins) agar (Nonomura 1969). Soil samples were pretreated at 80 °C for 1 h. One gram of soil sample collected from different locations was then suspended in 10 mL of sterile water individually. After vortexing, the supernatant was spread onto isolation media and grown for 7−14 days at 28 °C. Visible colonies were then transferred onto ISP2 agar (Shirling and Gottlieb 1966) for purification and long-term storage.

Microbial strain culture and identification

Strain XJ31 was isolated from a soil sample collected from Xinjiang, China, in July 2011, and maintained on ISP2 agar (4% glucose, 10% malt extract, 4% yeast extract, 2% agar, pH 7.0) at 28 °C. The identification of strain XJ31 was performed based on both morphological and 16S rDNA phylogenetic analysis. Mature aerial mycelium and substrate mycelium pigmentation were recorded on ISP2 agar media after incubation at 28 °C for 7 days. Genomic DNA extractions were carried out following a standard CTAB procedure as described in Practical Streptomyces Genetics (Kieser et al. 2000). A pair of primers (27F: 5′-GAGAGTTTGATCCTGGCTCAG-3′; 1492R: 5′-CTACGGCTACCTTGTTACGA-3′) was used to amplify the 16S rDNA. PCR (25 μL volume in total: contains 2.5 μL 10 × buffer (Takara), 2 μL 2.5 nM dNTP (Takara), 0.5 μL of each 20 μM primer, 1.5 U rTaq polymerase (Takara), and 1 μL DNA template) was performed on a Takara PCR Thermal Cycler with the initial denaturation at 95 °C for 5 min, followed by 28 cycles of denaturation (95 °C, 30 sec), annealing (55 °C, 30 sec) and elongation (72 °C, 1 min 30 s), and a final elongation at 72 °C for 10 min. Multiple sequence alignment of 16S rRNA gene with the related species was carried out using ClustalW (Thompson et al. 1994). A phylogenetic tree was constructed using the neighbor-joining method (Saitou and Nei 1987) by MEGA 7.0 (Tamura et al. 2011). Bootstrap values were calculated by resampling 1000 replicates (Felsenstein 1985).

Strain XJ31 has been deposited at the China General Microbiological Culture Collection Center (accession number 4.7298). The nucleotide sequences of the 16S rRNA gene have been deposited with NCBI (accession number KT951165).

Fermentation, extraction, and isolation

Twenty-one different actinomycete fermentation media (Table S2) were used for the small-scale fermentation of strain XJ31. Prior to fermentation, strain XJ31 was cultivated on an ISP2 agar plate at 28 °C for 5 days. Each 250-mL Erlenmeyer flask containing 40 mL of fermentation broth (5% of inoculum) was inoculated with a small portion (1 cm2) of mycelium on agar and grew for 7 days at 28 °C with shaking at 220 rpm. The fermentation broth was then extracted using 40 mL of a water/EtOAc (v/v: 1:1) solvent system, and the crude extracts were analyzed by HPLC-UV analysis with an Eclipse XDB-C8, 5 μm column (4.6 × 150 mm, Agilent) using a gradient elution: 5−99% ACN/H2O for 30 min, 99% ACN for 10 min.

Large-scale fermentation was performed using a two-step seed culture process. The primary seed culture used a 250-mL Erlenmeyer flask containing 40 mL of ISP2 medium which was inoculated with mycelium of XJ31 grown on ISP2 agar and incubated at 28 °C, at 220 rpm for 5 days. Aliquots (12 mL) of the primary seed culture were used to inoculate four 1-L Erlenmeyer flasks, each containing 250 mL of ISP2 broth to serve as a secondary seed culture. After incubation at 28 °C, 220 rpm for 5 days, aliquots (15 mL) of the secondary seed cultures were aseptically transferred into 80 1-L Erlenmeyer flasks each containing 250 mL of Noc05 fermentation medium (starch 1.0%, glucose 1.0%, glycerol 1.0%, corn steep 0.25%, peptone 0.5%, yeast extract 0.2%, NaNO3 0.1%, CaCO3 0.3%, pH natural), and fermentation was carried out at 28 °C, 220 rpm for 7 days. Fermentation broth was combined and centrifuged at 8000 rpm for 10 min to separate supernatant and mycelia cake. Supernatant was extracted three times with 20 L of the aforementioned water/EtOAc solvent system and the organic layer was combined and concentrated by rotary evaporation. The crude extract was initially fractionated using an ODS-MPLC (35 × 2.2 cm) using a stepwise gradient of 5−100% MeOH/H2O for 70 min and 100% MeOH for 40 min, yielding five fractions (fraction 1~5).

Fraction 5 was dried by rotary evaporation yielding 90 mg crude extract, which was then fractionated on a Sephadex LH-20 column (50 × 3 cm) in MeOH yielding six subfractions (fraction 5-1~5-6). Fraction 5-3 (5 mg) was further purified by reverse phase HPLC (ZORBAX RX-C8 9.4 × 250 mm, 5 μm column, 2.5 mL/min, gradient elution: 45% ACN/H2O for 30 min and 99% ACN for 10 min) yielding 13 (tR = 19.11 min; 1.0 mg) and 14 (tR = 28.38 min; 2.5 mg).

The mycelia cake was extracted three times with 1 L acetone and the organic layer was combined and concentrated by rotary evaporation. The crude extract (2.3 g) was passed through an ODS-MPLC (35 × 2.2 cm) developed by a stepwise gradient of 70−90% MeOH/H2O for 45 min, 90−100% MeOH for 30 min, 100% MeOH for 45 min, 100−90% MeOH/CH2Cl2 for 30 min, 90−80% MeOH/CH2Cl2 for 20 min, 80% MeOH/CH2Cl2 for 40 min, and 100% isopropanol for 50 min yielding seven fractions (fraction 6~12). LC-MS analysis and UV absorption characteristics revealed that fraction 8 contained a series of siderophore-type compounds. However, the purification was challenged due to the peak overlapping on HPLC as well as the different ion-chelating forms of siderophores. Thus, chelation with GaBr3 of fraction 8 solution was applied in order to stabilize all compounds in their Ga3+ chelation form for feasible purification. Fraction 8 (1.2 g) was dissolved in 400 mL MeOH and mixed with 2.5 g GaBr3 (dissolved in 6 mL MeOH) at room temperature for 1 h to yield fraction 8a. Fraction 8a was then fractionated by ODS-MPLC (35 × 2.2 cm) developed by a stepwise gradient of 85−100% MeOH/H2O for 60 min, 100% MeOH for 30 min, 100−90% MeOH/CH2Cl2 for 30 min, 90−80% MeOH/CH2Cl2 for 20 min, and 100% isopropanol for 30 min to yield subfractions (fractions 8a-1~8a-7). Fraction 8a-3 (126 mg) was further fractionated on reverse phase HPLC (ZORBAX RX-C8 9.4 × 250 mm, 5 μm column, 2.5 mL/min, isocratic elution with 68% ACN/H2O for 52 min) to give 1a (tR = 19.1 min; 13.7 mg), 4a (tR = 23.2 min; 8.7 mg), and 5a (tR = 28.4 min; 13.7 mg). Fraction 8a-4 (83.5 mg) was fractionated on reverse phase HPLC (ZORBAX RX-C8 9.4 × 250 mm, 5 μm column, 2.5 mL/min, isocratic elution with 63% ACN/H2O for 52 min) to give 2a (tR = 35.8 min; 10.5 mg), 6a (tR = 40.0 min; 5.5 mg), and 7a (tR = 51.0 min; 4.7 mg). Fraction 8a-5 (173 mg) was fractionated on reverse phase HPLC (ZORBAX RX-C3 9.4 × 250 mm, 5 μm column, 2.5 mL/min, eluted with 70% ACN/H2O for 36 min and 70−90% ACN/H2O for 9 min) to give 3a (tR = 25.4 min; 14.0 mg), 8a (tR = 30.5 min; 9.0 mg), and 9a (tR = 36.1 min; 5.7 mg). Fraction 8a-6 (300 mg) was first passed through a Sephadex LH-20 column developed by MeOH to yield four fractions (fraction 8a-6-1~8a-6-4). Fraction 8a-6-3 which contained the siderophores was further fractionated by reverse phase HPLC (ZORBAX RX-C8 9.4 × 250 mm, 5 μm column, 2.5 mL/min, isocratic elution with 63% ACN/H2O for 52 min) to obtain 10a (tR = 31.2 min; 3.0 mg), 11a (tR = 35.9 min; 2.8 mg), and 12a (tR = 41.6 min; 1.8 mg).

Anti-BCG bioassay

The anti-BCG bioactivity of isolated compounds was tested following the previously described procedure (Wang et al. 2013; Wayne 2002). The assay was performed with a strain of Mycobacterium bovis (BCG Pasteur 1173P2) containing a constitutive green fluorescent protein (GFP) expression vector (pUV3583c-GFP) using direct readout of fluorescence as a measure of bacterial growth, as described previously (Wang et al. 2010a, b). The BCG strain was pre-cultivated to mid-log phase (7 days) at 37 °C in Middlebrook 7H9 broth (40 mL; Difco) supplemented with 10% OADC enrichment (Becton Dickinson), 0.05% Tween-80, and 0.2% glycerol and then diluted to an OD600 of 0.025 with broth. A twofold serial dilution of each compound to be tested (4000 to 31.3 μg/mL in DMSO) was prepared and an aliquot of each dilution (2 μL) was added to a 96-well flat-bottom microtiter plate (Greiner). Isoniazid was used as the positive control and DMSO as the negative control. An aliquot (78 μL) of the BCG-GFP bacterial suspension was then added to each well (to give final compound concentrations of 100 to 0.78 μg/mL in 2.5% DMSO) and the plate was incubated at 37 °C for 3 days. Mycobacterial growth was determined by measuring GFP-fluorescence using an EnVision 2103 Multilabel Plate Reader (Perkin-Elmer Life Sciences) with excitation at 485 nm and emission at 535 nm. All the experiments were performed in triplicate. MIC was defined as the minimum concentration that inhibited more than 90% of bacteria growth.

Results

Isolation of rare actinomycete by selective isolation methods

We have isolated more than 600 actinobacterial strains from soil samples collected from 17 sampling sites in Xinjiang region (Fig. 1A and Table S3) using the five selective isolation media. All strains were de-replicated based on phenotype and morphology, and 260 actinobacteria strains were selected to build the culture library (data not shown). These actinobacteria strains isolated from Xinjiang environment exhibited a high degree of phenotypic diversity (Fig. 1B) and many of them showed distinct phenotypes from Streptomyces. The presence of these rare actinobacteria emphasizes the unique microbial diversity characteristic of the Xinjiang area and supports the idea of extreme diverse environment being an important resource for new chemical compounds. The phylogeny of these taxa was further investigated based on 16S rRNA gene sequence analysis: the 40 strains with distinct morphologies were subjected to systematic taxonomy analysis and were found to belong to 8 genera, including Micromonospora, Nocardia, Modestobacter, Glycomyces, Prauserella, Haloactinopolyspora, Plantactinospora, Polyangium, and Acinetobacter (Fig. 1B and Fig. S15). This diversified phylogeny composition underscores that the Actinobacteria of Xinjiang have great potential as a potential source of novel natural products. Among these 260 actinobacteria strains, strain XJ31 was identified as a new Nocardia species according to 16S rRNA phylogenetic analysis. Moreover, the HPLC profile of XJ31 exhibits high compound diversity and abundance; thus, strain XJ31 was chosen for detailed characterization.

Fig. 1.

Fig. 1

Open in a new tab

A survey of rare actinobacteria and anti-BCG compounds from Xinjiang region. (A) The sampling sites in Xinjiang region (Table S3). (B) Colony characteristics and overview of the rare actinomycete genera (assessed using 16S rRNA gene sequences) based on selected isolation of microbes. (C) Colony characteristics of the XJ31 strain, and the isolated anti-TB active compound brasiliquinone E

Characterization of strain XJ31 and structural elucidation and biological activities evaluation of its natural product compounds

After incubation at 28 °C for 7 days, strain XJ31 formed a puce-colored colony on ISP2 plates (Fig. 1C). No diffusible pigments were produced. Phylogenetic analysis of the strain’s 16S rRNA gene sequence (Fig. 2) demonstrated that strain XJ31 belongs to the genus Nocardia, exhibiting closest similarity to the 16S rRNA gene sequence of N. sungurluensis (97.94%) (Camas et al. 2014).

Fig. 2.

Fig. 2

Open in a new tab

Neighbor-joining phylogenetic tree based on 16S rRNA gene sequences from XJ31 and related species constructed using MEGA 7.0, with Rhodococcus rhodochrous DSM 43241T as the outgroup. Numbers at nodes indicate levels of bootstrap support (%) based on a neighbor-joining analysis of 1000 resampled datasets. NCBI accession numbers are given. Bar, 0.01 nucleotide substitutions per site

HPLC analysis of crude extracts from XJ13 fermentation broth supernatant revealed an apparently diverse profile of natural product compounds (Fig. 3A). Using the fractionation scheme detailed in the “Materials and methods” section, multiple compounds were purified, and subsequent anti-BCG bioassay-guided isolation led to the isolation of two benz[α]anthraquinones, brasiliquinones D (13) and E (14) (Fig. 3B). Furthermore, siderophores detected in fraction 8 were chelated with Ga3+ prior to purification. The iron complex of siderophores is typically stable and easy for separation; however, the ferric iron present in ferric siderophore exists in a paramagnetic high spin d5 state which causes severe line broadening of the NMR signals. Thus, Ga3+ or the Al3+ siderophore complexes are usually employed for NMR experiments (Jalal and van der Helm 1991). A 10-fold excess of GaBr3 was added into fraction 8 and clearly separated peaks were apparent in HPLC analyses of siderophore-containing fractions (Fig. 4A). Meanwhile, a metal-to-ligand charge transfer band at λmax = 340 nm (Seyedsayamdost et al. 2011) was observed (Fig. 4C), compared with the band at λmax = 308 nm for Ga3+ free-siderophores (Fig. 4B). After chelation with GaBr3, twelve Ga-siderophores complexes (1a−12a) were subsequently purified and used for acquisition of NMR spectra, which allowed the structural elucidation of nocardimicins B, D, F, and J~R (1−12) (Fig. 3B). Among these identified siderophores, 4−12 and 14 are previously unreported structures.

Fig. 3.

Fig. 3

Open in a new tab

HPLC-UV profiles of crude extracts of strain XJ31 cultured in medium (A). Noc05 and structures of isolated compounds (1−14) (B)

Fig. 4.

Fig. 4

Open in a new tab

HPLC profiles of siderophores-containing fraction (upper panel of A) and chelation with GaBr3 (lower panel of A). UV spectra of siderophores (B) and their Ga3+ complexes (C)

Compound 4a was isolated as a white powder. The molecular formula was deduced as C40H58N5O10Ga based on HR-ESI-MS data (Fig. S4a) (m/z 838.3530 [M + H]+, calcd. for 838.3512) with 13 degrees of unsaturation. Combined analysis of 1H NMR, 13C NMR, and HSQC spectra (Figs. S4b–S4d) of 4a indicated the presence of two amide protons (δH 10.11 and 7.94), a 1,2-disubstituted benzene moiety (δC/δH 167.6, 135.4/7.39, 128.1/8.01, 123.4/7.30, 117.0/6.79, and 112.5), three methyl groups (δC/δH 17.2/1.35, 14.8/0.88, and 10.1/1.03), five carbonyl carbons (δC 172.2, 171.9, 166.8, 163.9, and 159.9), three additional aromatic carbons (δC 166.3, 143.2, and 136.4), one oxymethine (δC/δH 78.1/5.36), two nitrogen-bearing methylenes (δC/δH 53.5/3.45 and 49.3/4.00), two nitrogen-bearing methine (δC/δH 55.7/4.83 and 45.8/2.95), 17 methylenes, and one methine (Table S4). These data revealed that 4a had a nocardimicin-type framework, by comparison with those of previously reported compounds (Ikeda et al. 2005).

The 1H-1H COSY and HMBC experiments (Figs. S4e and S4f) of 4a revealed four sub-structures A~D shown in Fig. 5: a hydroxyphenyloxazoline, a fatty acid moiety, and two lysine-derived moieties. The sub-structure A was determined by HMBC correlations from H-3 to C-1 and C-5, from H-6 to C-2, C-4, and C-7, and from H-9 to C-7, C-10, and C-12. The proton spin systems of sub-structure B could be determined by COSY correlations of H-13/H-14, H-14/H-28b, H-28/H-29, H-29a/H-30b, and H-30/H-31 and correlation of H-34/H-52. HMBC correlations from ε-methylene proton H-31 and a triplet methyl proton H-52 to C-33 indicated the presence of a propanoyl group at N-32. The sub-structure B was thus determined as Nε-propanoyllysine. Sub-structure C was elucidated as 2-methyl-3-hydroxytetradecanoid acid according to the COSY correlations shown in blue color, together with HMBC correlations from H-17 and H-54 to C-19. Sub-structure D was deduced from HMBC correlations of H-21/C-22, H-20/C-22, and H-24/C-22.

Fig. 5.

Fig. 5

Open in a new tab

Key COSY and HMBC correlations for compounds 4 and 14

The organization of the sub-structures was determined based on HMBC experiments (Fig. S4f). The relationship of sub-structures A and B was confirmed by HMBC correlation from H-13 to C-12. The connectivity of sub-structures B and C was established by the HMBC correlation of H-17/C-15 through an ester bond. The HMBC correlations from H-20 and H-21 to C-19 indicated the linkage of the sub-structures C and D through an amide bond. Based on molecular formula of 4a, the remaining two hydroxyl groups were assigned as substituents at the nitrogen atoms N-23 and N-32. All of the signals in the 2D NMR spectra were assigned unambiguously (Table S4). These data supported the structure assigned to nocardimicin J (4) (Fig. 3), the Ga3+ free form of 4a.

The molecular formulae of Ga3+-chelated nocardimicins L (6a), N (8a), and Q (11a) were deduced as C42H62N5O10Ga, C44H66N5O10Ga, and C46H70N5O10Ga, respectively, according to their HR-ESI-MS ([M + H]+ m/z 866.3836, 894.4152, and 922.4458) (Figs. S6a, S8a, and S11a). 1H and 13C NMR data of these compounds (Figs. S6b, S6c, S8b, S8c, S11b, and S11c) were very similar to those of 4a. The ion mass of 6a was 28 mass units (C2H4) larger than that of 4a; the mass of 8a was 56 mass units (C4H8) larger than 4a, and that of 11a was 84 mass units (C6H12) larger than 4a. These data indicated that these compounds were the analogs of 4a differing in their fatty acid chain lengths. All of the signals in the 2D NMR spectra of these compounds were assigned unambiguously (Figs. S6d–S6f, S8d–S8f, and S11d–S11f; Tables S6, S8, and S11). Based on these data, the structures of the Ga3+ free form of 6a, 8a, and 11a were determined as nocardimicins L (6), N (8), and Q (11) (Fig. 3).

Compound 5a was isolated as a white powder. The molecular formula was determined to be C41H60N5O10Ga based on HR-ESI-MS (Fig. S5a) (m/z 852.3677 [M + H]+, calcd. for 852.3669) with 13 degrees of unsaturation. 1H and 13C NMR data (Figs. S5b and S5c) of 5a were very similar to those of 4a, except the presence of an extra methylene group (δC/δH 19.4/1.66-1.56). The COSY (Fig. S5d) correlations of H-34/H-52 and H-52/H-53 revealed the existence of propyl group. The HMBC (Fig. S5f) correlations of H-34/C-33, H-34/C-52, H-52/C-33, H-52/C-53, H-53/C-34, and H-53/C-52 indicated the attachment of a butanoyl group at N-32 of the lysine unit. Thus, the structure of the Ga3+ free form of 5a was analyzed via 2D NMR spectra (Figs. S5d–S5f; Table S5), and it was determined to be nocardimicin K (5) (Fig. 3). The 1H and 13C NMR data for 7a, 9a, and 12a (Figs. S7b, S7c, S9b, S9c, S12b, and S12c) were very similar to those of 5a: their HR-ESI-MS spectra indicated that these compounds are analogs of 5a differing in their fatty acid chain lengths. The molecular formulae of 7a, 9a, and 12a were determined to be C43H64N5O10Ga, C45H68N5O10Ga, and C47H72N5O10Ga, respectively, according to their HR-ESI-MS data ([M + H]+ m/z 880.3991, 908.4299, and 936.4622) (Figs. S7a, S9a, and S12a). The ion mass of 7a was 28 mass units (C2H4) larger than that of 5a, that of 9a was 56 mass units (C4H8) larger, and that of 12a was 84 mass units (C6H12) larger. All of the signals in 2D NMR spectra of these compounds were assigned unambiguously (Figs. S7d–S7f, S9d–S9f, and S12d–S12f; Tables S7, S9, and S12). Based on these data, the structures of the Ga3+ free forms of 7a, 9a, and 12a were determined as nocardimicins M (7), O (9), and R (12) (Fig. 3).

Compound 10a was isolated as a white powder. The molecular formula was determined to be C45H68N5O10Ga based on HR-ESI-MS (Fig. S10a) (m/z 908.4301 [M + H]+, calcd. for 908.4295) with 13 degrees of unsaturation. 1H and 13C NMR data of 10a (Figs. S10b and S10c) were very similar to those of 11a, except for the absence of a methylene group. The HMBC (Fig. S10f) correlation between the methyl group CH3-34 (δC/δH 16.8/2.03) and the carbonyl group (C-33) indicated attachment of an acetyl group at N-32 of the lysine unit. Thus, the structure of the Ga3+ free form of 10a was determined to be nocardimicin P (10) (Figs. 3, S10d, and S10e; Table S10).

The structures of the three known siderophores, nocardimicin B (1), nocardimicin D (2), nocardimicin F (3), were determined based on the HR-ESI-MS, 1H NMR, and 13C NMR data of their Ga3+-chelated products 1a, 2a, and 3a (Figs. S1–S3), respectively, and by comparison with those of previous reports (Ikeda et al. 2005).

Compound 13 was obtained as a yellow amorphous powder. The molecular formula of 13 was established as C28H29NO8 on the basis of its HR-ESI-MS data (m/z 508.1978 [M + H]+, calcd. for 508.1966) (Fig. S13a). Compound 13 was determined to be brasiliquinone D according to combined analysis of its UV, 1H NMR, and 13C NMR spectra (Figs. S13b-S13d; Table S13) and via comparison with previously reported data (Tsuda et al. 1999).

Compound 14 was obtained as a yellow amorphous powder and its molecular formula of 14 was deduced as C27H27NO8 on the basis of HR-ESI-MS data (m/z 494.1828 [M + H]+, calcd. for 494.1809) (Fig. S14a). The UV spectrum of 14 (Fig. S14b) was identical to that of 13, a finding indicating that these compounds both share the same benz[α]anthraquinone skeleton. The molecular mass of 14 was 14 mass units smaller than that of 13, indicating a difference of one CH2 in their structures. The 1H and 13C NMR data (Figs. S14c and S14d) of 14 were similar to those of 13, except the absence of a CH2 group (δC/δH 29.0/1.53). The structure of 14 was analyzed via 2D NMR (Figs. 5 and S14e-S14g; Tables 1 and S14) and was determined to be the previously unreported compound brasiliquinone E.

Table 1.

NMR data (500 MHz for 1H NMR and 125 MHz for 13C NMR, CD3OD) for Brasiliquinone E (14)

Pos. δC δH, mult (J in Hz) COSY HMBC
1 200.3
2 49.1 2.83, dd (15.5, 4.7) 2b, 3 1
2.53, m 3 1, 3, 13
3 31.9 2.38, m
4 39.2 3.02, dd (16.7, 3.9) 3, 4b 4a, 12b
2.7, dd (16.7, 10.6) 3 2, 3, 4a, 5, 12b, 13
4a 154.6
5 122.1 7.08, s 4, 6, 6a, 12b
6 164.8
6a 119.0
7 190.2
7a 122.1
8 158.4
9 121.7 7.75, d (9.0) 10 11
10 137.8 7.83, t (8.0) 9, 11 8, 11a
11 121.2 7.73, d (7.7) 10 8, 12
11a 138.8
12 185.6
12a 139.0
12b 129.3
13 21.6 1.18, d (6.6) 2, 3, 4
1′ 96.8 5.97, d (3.2) 2′a 3′, 5′
2′ 34.4 2.35, m 2′b
2.22, dd (15.0, 1.4) 1′, 3′, 4′
3′ 47.4 4.65, m 2′a, 4′
4′ 73.7 3.52, dd (10.0, 4.3) 5′, 6′
5′ 66.9 3.83, m 4′, 6′
6′ 18.1 1.19, d (6.2) 4′, 5′
3′-NAc 174.5
3′-NAc 23.4 2.25, s 3′-NAc
Open in a new tab

The anti-BCG activity of the isolated compounds was evaluated, and the two benz[α]anthraquinones 13 and 14 both showed potent activity against BCG, with MIC values of around 25 μM.

Discussion

From the late 1940s to 1960s, many new antibiotics were isolated from actinobacteria during the Golden Age of antibiotic discovery. Approximately 60% of these antibiotics were discovered from the genus Streptomyces (Bérdy 2012). More recently, there has been extensive overlap in the reported compounds isolated from Streptomyces species, a situation which has guided research attention away from this taxon and towards non-Streptomyces actinobacteria, which are sometimes referred to as “rare actinobacteria” (Subramani and Aalbersberg 2013; Subramani and Sipkema 2019). Unexplored (and underexplored) ecological environments are promising sources for the discovery of rare actinobacteria, and these organisms are believed to be rich sources for structurally diverse, yet unknown, compounds (Dhakal et al. 2017).

Xinjiang area harbors lots of highly diversified ecological environments, including salt lakes, deserts, and plateaus with saline-alkali soils. Our previous efforts to isolate rare actinobacteria from extreme environments such as work in the South China Sea and a Xinjiang desert have successfully described a series of new species from genera including Verrucosispora and Prauserella (Dai et al. 2010; Liu et al. 2014b; Wang et al. 2010a, b). In the present study, we continued a survey of the biological diversity of actinobacteria from the Xinjiang region and explored the potential anti-TB activity of NPs present in previously unknown strains. Using a selective isolation method, 40 rare actinobacteria belonging to eight genera were isolated from 17 samples collected in Xinjiang region. Among these rare genera, Micromonospora and Nocardia were dominant, representing 49% and 26% of the strains, respectively.

Further phylogenetic analysis based on 16S rRNA gene sequences emphasized the rarity of an actinomycete strain which we deemed Nocardia sp. XJ31 and that showed the highest similarity to N. goodfellowii (97.81%). The natural product profile of XJ31 was evaluated using an OSMAC approach. Two classes of NPs, siderophores (1−12) and anthraquinones (13 and 14), were thusly identified from strain XJ31 fermentation extracts, including ten new compounds (nocardimicins J−R and brasiliquinone E).

According to earlier reports, nearly 40% of anti-mycobacterial compounds have been isolated from genera including Amycolatopsis, Nocardia, Actinomadura, Bacillus, Pleurotus, and Saccharopolyspora, all of which are similar to Mycobacterium strains (Ashforth et al. 2010; Butler and Buss 2006). Mukai et al. (2009) reported that a novel thiopeptide nocardithiocin, isolated from the pathogenic N. pseudobrasiliensis strain IFM 0757, was highly active against rifampicin-resistant as well as rifampicin-sensitive TB strains, exhibiting a range of MIC values from 0.025 to 1.56 μg/mL. Our findings in the present study revealed that two anthraquinones, brasiliquinones D (13) and E (14), showed moderate anti-BCG activity (MIC = 25 μM). Brasiliquinones were originally discovered from Nocardia brasiliensis by Tsuda et al. (1996). Brasiliquinone A−C exhibited anti-bacterial activity against M. smegmatis, in agreement with anti-BCG activity of brasiliquinone E in this study. The inspiration of looking for novel natural products with anti-TB activity was driven by the fact that the multi-drug resistance tuberculosis (MDR-TB) is rising with the current treatment such as isoniazid (MIC = 1.4 μM) and rifampin (MIC = 0.3 μM) (Lee and Heifets 1987). Although brasiliquinones do not have comparable activity as indicated by MIC level, they still represent potential application value considering the drug resistance issue.

Nocardimicins A−F were discovered from Nocardia sp. TP-A0674 in the screening for muscarinic M3 receptor–binding inhibitors (Ikeda et al. 2005); thus, they are identified as potential candidates for neurotransmission disorder treatment. There has no reported anti-bacterial activity with nocardimicins, neither nocardimicins A−J exhibited inhibitory activity on BCG, MRSA, S. aureus, and B. subtilis (data not shown) analyzed with our inhouse bioassay. Besides, it is well known that iron is one of the major limiting factors and essential nutrients of microbial life (Litwin and Calderwood 1993). The nocardimicins represent the bulk of the NPs produced in Nocardia sp. XJ31; thus, the high yield could be the bacteria’s response to the environment stress.

In nature, microorganisms produce small, high-affinity chelating molecules referred to as siderophores to facilitate their acquisition of iron (Saha et al. 2013). There are three types of siderophores, i.e., hydroxamates, catecholates, and carboxylates (Ali and Vidhale 2013). These molecules have been widely used in agricultural (Chaiharn et al. 2008), environmental (Ruggiero et al. 2000), and biomedical applications. In agriculture, siderophores have been used as biocontrol agents (Husen 2016), and the biomedical application of these compounds has exploited their anti-cancer (Chua et al. 2003), anti-malarial (Breidbach et al. 2002; Gysin et al. 1993), and anti-infectious (Wooldridge and Williams 1993) activities. Miller et al. (2011) reported that when conjugated with mycobactin analogs, the anti-malarial agent artemisinin exhibits activity against M. tuberculosis. Conjugates of siderophores and antibiotics are called “Trojan horse” antibiotics, in which the antibiotic compound utilizes the siderophores as a mediator for entry into cells via the iron-uptake machinery (Möllmann et al. 2009; Ratledge and Dover 2000). Hence, the discovery of new siderophores with antibiotic properties provides valuable materials and insights that can drive drug discovery and development efforts.

In addition, we have performed computer-aided virtual screening on compounds in this study to look for potential viral development inhibitors (supplementary document). Lassa virus polymerase (PDB ID: 6KLC), Machupo virus polymerase (PDB ID: 6KLE), Influenza A virus polymerase (PDB ID: 6QX3), and Influenza D virus polymerase (PDB ID: 6KUJ) are key enzymes for virus replication. Notably, all the isolated compounds were docked onto the active site of 3′-RNA pocket of virus polymerases to evaluate their binding affinities by using Gold program (Jones et al. 1997). Siderophores nocardimicins A−J (1−12) exhibited significant binding affinities with the four 3’′-RNA pockets of virus polymerases (> 90%) (Table S13). Virus infection severely affected healthy human beings (Peters et al. 1996); especially the emerging outbreak of COVID-2019 caused by SARS-CoV-2 (Zhu et al. 2019) highlights the urgent need of developing broad-spectrum antivirus drugs. Our preliminary data revealed important potentials of these siderophores for broad-spectrum antivirus drug development. Cell-based evaluation of virus polymerases inhibitory effects of these siderophores is ongoing.

This study expands the knowledge about the distribution and biodiversity of rare actinobacteria and their corresponding bioactive chemical entities from diverse environments in Xinjiang. Among the rare actinobacteria genera of our study, the genus Nocardia is the second most prevalent, and we show that Nocardia sp. XJ31 exerts anti-BCG activity by producing anthraquinone-type compounds. This study offers a strategy to investigate new bioactive compounds from microbes in extreme habitats.

Electronic supplementary material

ESM 1 (8.7MB, pdf)

(PDF 8858 kb).

Acknowledgments

L. Zhang would like to thank the China Scholarship Council for the provision of China Government scholarship to support her Ph.D. study in the USA.

Author contributions

XL and HD conceived and devised the project. Li Zhang, JZ, BR, WL, and CH participated in the experiments. JW, XM, ML, and ZL isolated and identified the strains. RM and HD performed the bioactivity screen of these isolated compounds. JPL and KD performed the virtual screening for virus inhibitor. HD, XL, and LZ supervised the project. Li Zhang, JZ, and XL wrote the manuscript. All authors read and approved the manuscript.

Funding information

This study was financially supported by the National Key Research and Development Program of China (2019YFA0906200), the National Natural Science Foundation of China (31720103901, 21877038, 21977029, 21877124, 81573341), Shanghai Rising-Star Program (20QA1402800), the Open Project Funding of the State Key Laboratory of Bioreactor Engineering, the 111 Project (B18022), Shanghai Science and Technology Commission (18JC1411900).

Compliance with ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare that they have no conflicts of interest.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Li Zhang and Jingyu Zhang contributed equally to this work.

Contributor Information

Huanqin Dai, Email: daihq@im.ac.cn, Email: daihuanqin@139.com.

Xueting Liu, Email: liuxueting@ecust.edu.cn.

References

  1. Ali SS, Vidhale N. Bacterial siderophore and their application: a review. Int J Curr Microbiol App Sci. 2013;2(12):303–312. [Google Scholar]
  2. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223–227. doi: 10.1126/science.1106753. [DOI] [PubMed] [Google Scholar]
  3. Ashforth EJ, Fu C, Liu X, Dai H, Song F, Guo H, Zhang L. Bioprospecting for antituberculosis leads from microbial metabolites. Nat Prod Rep. 2010;27(11):1709–1719. doi: 10.1039/c0np00008f. [DOI] [PubMed] [Google Scholar]
  4. Bérdy J. Thoughts and facts about antibiotics: where we are now and where we are heading. J Antibiot. 2012;65(8):385–395. doi: 10.1038/ja.2012.27. [DOI] [PubMed] [Google Scholar]
  5. Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med. 2015;373(20):1986–1988. doi: 10.1056/NEJMc1505196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Breidbach T, Scory S, Krauth-Siegel RL, Steverding D. Growth inhibition of bloodstream forms of Trypanosoma brucei by the iron chelator deferoxamine. Int J Parasitol. 2002;32(4):473–479. doi: 10.1016/S0020-7519(01)00310-1. [DOI] [PubMed] [Google Scholar]
  7. Butler MS, Buss AD. Natural products—the future scaffolds for novel antibiotics? Biochem Pharmacol. 2006;71(7):919–929. doi: 10.1016/j.bcp.2005.10.012. [DOI] [PubMed] [Google Scholar]
  8. Camas M, Veyisoglu A, Sahin N. Nocardia sungurluensis sp. nov., isolated from soil. Int J Syst Evol Microbiol. 2014;64(5):1629–1634. doi: 10.1099/ijs.0.051334-0. [DOI] [PubMed] [Google Scholar]
  9. Chaiharn M, Chunhaleuchanon S, Kozo A, Lumyong S. Screening of rhizobacteria for their plant growth promoting activities. Cur Appl Sci Technol. 2008;8(1):18–23. [Google Scholar]
  10. Chua ACG, Ingram HA, Raymond KN, Baker E. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells. Eur J Biochem. 2003;270(8):1689–1698. doi: 10.1046/j.1432-1033.2003.03525.x. [DOI] [PubMed] [Google Scholar]
  11. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta Gen Subj. 2013;1830(6):3670–3695. doi: 10.1016/j.bbagen.2013.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dai HQ, Wang J, Xin YH, Pei G, Tang SK, Ren B, Ward A, Ruan J-S, Li WJ, Zhang LX. Verrucosispora sediminis sp. nov., a cyclodipeptide-producing actinomycete from deep-sea sediment. Int J Syst Evol Microbiol. 2010;60(8):1807–1812. doi: 10.1099/ijs.0.017053-0. [DOI] [PubMed] [Google Scholar]
  13. Dhakal D, Pokhrel AR, Shrestha B, Sohng JK. Marine rare actinobacteria: Isolation, characterization, and strategies for harnessing bioactive compounds. Front Microbiol. 2017;8:1106. doi: 10.3389/fmicb.2017.01106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291–360. doi: 10.1016/S2213-2600(17)30079-6. [DOI] [PubMed] [Google Scholar]
  15. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39(4):783–791. doi: 10.1111/j.1558-5646.1985.tb00420.x. [DOI] [PubMed] [Google Scholar]
  16. Gysin J, Crenn Y, da Silva LP, Breton C (1993) Siderophores as antiparasitic agents. Google Patents
  17. Hayakawa M, Nonomura H. Humic acid-vitamin agar, a new medium for the selective isolation of soil actinomycetes. J Ferment Technol. 1987;65(5):501–509. doi: 10.1016/0385-6380(87)90108-7. [DOI] [Google Scholar]
  18. Huang P, Xie F, Ren B, Wang Q, Wang J, Wang Q, Abdel-Mageed WM, Liu M, Han J, Oyeleye A. Anti-MRSA and anti-TB metabolites from marine-derived Verrucosispora sp. MS100047. Appl Microbiol Biotechnol. 2016;100(17):7437–7447. doi: 10.1007/s00253-016-7406-y. [DOI] [PubMed] [Google Scholar]
  19. Husen E. Screening of soil bacteria for plant growth promotion activities in vitro. Indonesian J AgrIC Sci. 2016;4(1):27–31. doi: 10.21082/ijas.v4n1.2003.p27-31. [DOI] [Google Scholar]
  20. Ikeda Y, Nonaka H, Furumai T, Onaka H, Igarashi Y. Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005;68(7):1061–1065. doi: 10.1021/np050091j. [DOI] [PubMed] [Google Scholar]
  21. Jalal M, van der Helm D. Handbook of microbial iron chelates. Boca Raton: CRC Press; 1991. Isolation and spectroscopic identification of fungal siderophores; pp. 235–269. [Google Scholar]
  22. Jiang W, Zhong Y, Shen L, Wu X, Ye Y, Chen C-TA WB. Stress-driven discovery of natural products from extreme marine environment-Kueishantao hydrothermal vent, a case study of metal switch valve. Curr Org Chem. 2014;18(7):925–934. doi: 10.2174/138527281807140515155705. [DOI] [Google Scholar]
  23. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(3):727–748. doi: 10.1006/jmbi.1996.0897. [DOI] [PubMed] [Google Scholar]
  24. Katz L, Baltz RH. Natural product discovery: past, present, and future. J Ind Microbiol Biotechnol. 2016;43(2-3):155–176. doi: 10.1007/s10295-015-1723-5. [DOI] [PubMed] [Google Scholar]
  25. Kieser T, Bibb M, Buttner M, Chater K, Hopwood D (2000) Growth and preservation of Streptomyces. Practical Streptomyces Genetics:43–61
  26. Küster E, Williams S (1964) Selection of media for isolation of Streptomycetes. Nature 202(4935):928–929. 10.1038/202928a0 [DOI] [PubMed]
  27. Lee CN, Heifets LB. Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods. Am Rev Respir Dis. 1987;136(2):349–352. doi: 10.1164/ajrccm/136.2.349. [DOI] [PubMed] [Google Scholar]
  28. Litwin CM, Calderwood S. Role of iron in regulation of virulence genes. Clin Microbiol Rev. 1993;6(2):137–149. doi: 10.1128/CMR.6.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Liu X, Chen C, He W, Huang P, Liu M, Wang Q, Guo H, Bolla K, Lu Y, Song F. Exploring anti-TB leads from natural products library originated from marine microbes and medicinal plants. Anton Leeuw Int J G. 2012;102(3):447–461. doi: 10.1007/s10482-012-9777-0. [DOI] [PubMed] [Google Scholar]
  30. Liu M, Abdel-Mageed WM, Ren B, He W, Huang P, Li X, Bolla K, Guo H, Chen C, Song F. Endophytic Streptomyces sp. Y3111 from traditional Chinese medicine produced antitubercular pluramycins. Appl Microbiol Biotechnol. 2014;98(3):1077–1085. doi: 10.1007/s00253-013-5335-6. [DOI] [PubMed] [Google Scholar]
  31. Liu M, Zhang L, Ren B, Yang N, Yu X, Wang J, Ding L, Liu X, Liu Z, Goodfellow M. Prauserella shujinwangii sp. nov., from a desert environment. Int J Syst Evol Microbiol. 2014;64(11):3833–3837. doi: 10.1099/ijs.0.065425-0. [DOI] [PubMed] [Google Scholar]
  32. Liu M, Grkovic T, Zhang L, Liu X, Quinn RJ. A model to predict anti-tuberculosis activity: value proposition for marine microorganisms. J Antibiot. 2016;69(8):594–599. doi: 10.1038/ja.2016.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466. doi: 10.1371/journal.pmed.0030466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Meklat A, Sabaou N, Zitouni A, Mathieu F, Lebrihi A. Isolation, taxonomy, and antagonistic properties of halophilic actinomycetes in Saharan soils of Algeria. Appl Environ Microbiol. 2011;77(18):6710–6714. doi: 10.1128/AEM.00326-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Mesfin YM, Hailemariam D, Biadglign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS One. 2014;9(1):e82235. doi: 10.1371/journal.pone.0082235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Miller MJ, Walz AJ, Zhu H, Wu C, Moraski G, Moellmann U, Tristani EM, Crumbliss AL, Ferdig MT, Checkley L, Edwards RL, Boshoff Helena I. Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. J Am Chem Soc. 2011;133(7):2076–2079. doi: 10.1021/ja109665t. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Möllmann U, Heinisch L, Bauernfeind A, Köhler T, Ankel-Fuchs D. Siderophores as drug delivery agents: application of the “Trojan Horse” strategy. Biometals. 2009;22(4):615–624. doi: 10.1007/s10534-009-9219-2. [DOI] [PubMed] [Google Scholar]
  38. Mukai A, Fukai T, Hoshino Y, Yazawa K, Harada K-i, Mikami Y. Nocardithiocin, a novel thiopeptide antibiotic, produced by pathogenic Nocardia pseudobrasiliensis IFM 0757. J Antibiot. 2009;62(11):613–619. doi: 10.1038/ja.2009.90. [DOI] [PubMed] [Google Scholar]
  39. Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629–661. doi: 10.1021/acs.jnatprod.5b01055. [DOI] [PubMed] [Google Scholar]
  40. Nonomura H. Distribution of actinomycetes in soil.(VI) A culture method effective for both preferential isolation and enumeration of Microbispora and Streptosporangium in soil (Part I) J Ferment Technol. 1969;47:463–469. [Google Scholar]
  41. Okoro CK, Brown R, Jones AL, Andrews BA, Asenjo JA, Goodfellow M, Bull AT. Diversity of culturable actinomycetes in hyper-arid soils of the Atacama Desert, Chile. Anton Leeuw Int J G. 2009;95(2):121–133. doi: 10.1007/s10482-008-9295-2. [DOI] [PubMed] [Google Scholar]
  42. Peters CJ, Jahrling PB, Khan AS. Patients infected with high-hazard viruses: scientific basis for infection control. In: Schwarz TF, Siegl G, editors. Imported virus infections. Archives of Virology Supplement II. Vienna: Springer; 1996. [DOI] [PubMed] [Google Scholar]
  43. Pettit RK. Culturability and secondary metabolite diversity of extreme microbes: expanding contribution of deep sea and deep-sea vent microbes to natural product discovery. Mar Biotechnol. 2011;13(1):1–11. doi: 10.1007/s10126-010-9294-y. [DOI] [PubMed] [Google Scholar]
  44. Ratledge C, Dover LG. Iron metabolism in pathogenic bacteria. Annu Rev Microbiol. 2000;54(1):881–941. doi: 10.1146/annurev.micro.54.1.881. [DOI] [PubMed] [Google Scholar]
  45. Ruggiero C, Neu M, Matonic J, Reilly S. Interactions of Pu with desferrioxamine siderophores can affect bioavailability and mobility. Actinide Res Q. 2000;2000:16–18. [Google Scholar]
  46. Saha R, Saha N, Donofrio RS, Bestervelt LL. Microbial siderophores: a mini review. J Basic Microbiol. 2013;53(4):303–317. doi: 10.1002/jobm.201100552. [DOI] [PubMed] [Google Scholar]
  47. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4(4):406–425. doi: 10.3390/molecules23061371. [DOI] [PubMed] [Google Scholar]
  48. Seyedsayamdost MR, Traxler MF, Zheng S-L, Kolter R, Clardy J. Structure and biosynthesis of amychelin, an unusual mixed-ligand siderophore from Amycolatopsis sp. AA4. J Am Chem Soc. 2011;133(30):11434–11437. doi: 10.1021/ja203577e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Shirling ET, Gottlieb D. Methods for characterization of Streptomyces species. Int J Syst Bacteriol. 1966;16(3):313–340. doi: 10.1099/00207713-16-3-313. [DOI] [Google Scholar]
  50. Subramani R, Aalbersberg W. Culturable rare actinomycetes: diversity, isolation and marine natural product discovery. Appl Microbiol Biotechnol. 2013;97(21):9291–9321. doi: 10.1007/s00253-013-5229-7. [DOI] [PubMed] [Google Scholar]
  51. Subramani R, Sipkema D. Marine rare actinomycetes: a promising source of structurally diverse and unique novel natural products. Mar Drugs. 2019;17(5):249. doi: 10.3390/md17050249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731–2739. doi: 10.1093/molbev/msr121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Tan GYA, Ward AC, Goodfellow M. Exploration of Amycolatopsis diversity in soil using genus-specific primers and novel selective media. Syst Appl Microbiol. 2006;29(7):557–569. doi: 10.1016/j.syapm.2006.01.007. [DOI] [PubMed] [Google Scholar]
  54. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673–4680. doi: 10.1093/nar/22.22.4673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Tsuda M, Sato H, Tanaka Y, Yazawa K, Mikami Y, Sasaki T, Kobayashi J. Brasiliquinones A–C, new cytotoxic benz[a]anthraquinones with an ethyl group at C-3 from actinomycete Nocardia brasiliensis. J Chem Soc Perkin Trans. 1996;1:1773–1775. doi: 10.1039/P19960001773. [DOI] [Google Scholar]
  56. Tsuda M, Nemoto A, Komaki H, Tanaka Y, Yazawa K, Mikami Y, Ji K. Nocarasins A−C and brasiliquinone D, new metabolites from the actinomycete Nocardia brasiliensis. J Nat Prod. 1999;62(12):1640–1642. doi: 10.1021/np990265v. [DOI] [Google Scholar]
  57. Wang JF, Dai HQ, Wei YL, Zhu HJ, Yan YM, Wang YH, Long CL, Zhong HM, Zhang LX, Cheng YX. Antituberculosis agents and an inhibitor of the para-aminobenzoic acid biosynthetic pathway from hydnocarpus anthelminthica seeds. Chem Biodivers. 2010;7(8):2046–2053. doi: 10.1002/cbdv.201000072. [DOI] [PubMed] [Google Scholar]
  58. Wang J, Li Y, Bian J, Tang SK, Ren B, Chen M, Li WJ, Zhang LX. Prauserella marina sp. nov., isolated from ocean sediment of the South China Sea. Int J Syst Evol Microbiol. 2010;60(4):985–989. doi: 10.1099/ijs.0.013862-0. [DOI] [PubMed] [Google Scholar]
  59. Wang Q, Song F, Xiao X, Huang P, Li L, Monte A, Abdel-Mageed WM, Wang J, Guo H, He W. Abyssomicins from the South China Sea deep-sea sediment Verrucosispora sp.: natural thioether michael addition adducts as antitubercular prodrugs. Angew Chem Int Ed. 2013;52(4):1231–1234. doi: 10.1002/anie.201208801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Wayne P (2002) National committee for clinical laboratory standards. Performance standards for antimicrobial disc susceptibility testing 28th ed. CLSI supplement M100
  61. WHO Global Tuberculosis Report (2018) https://www.who.int/tb/publications/global_report/en/. Accessed 26 September 2018.
  62. Wooldridge KG, Williams PH. Iron uptake mechanisms of pathogenic bacteria. FEMS Microbiol Rev. 1993;12(4):325–348. doi: 10.1111/j.1574-6976.1993.tb00026.x. [DOI] [PubMed] [Google Scholar]
  63. Zhu N, Zhang DY, Wang WL, Li XW, Yang B, Song JD, Zhao X, Huang BY, Shi WF, Lu RJ, Niu PH, Zhan FX, Ma XJ, Wang DY, Xu WB, Wu GZ, Gao GF, Tan WJ. A novel coronavirus from patients with pneumonia in china, 2019. N Engl J Med. 2019;382:727–733. doi: 10.1056/NEJMoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ESM 1 (8.7MB, pdf)

(PDF 8858 kb).

Articles from Applied Microbiology and Biotechnology are provided here courtesy of Nature Publishing Group

RESOURCES